AstraZeneca bets on insitro’s AI platform to find disease targets
AstraZeneca has signed a multi-year deal with AI biotech insitro to search for new treatments for liver and heart conditions. The headline is the division of labour: insitro will use machine learning and lab-grown cell models to identify di
Open discussion →